Seeking Alpha
View as an RSS Feed

KarinCA  

View KarinCA's Comments BY TICKER:
Latest  |  Highest rated
  • Cellceutix: Small Biotech With High Risk / High Reward Profile [View article]
    The Brilacidin-OM trial should be giving us a good indication of whether or not it's working by end of year. The company has announced the addition of two additional trial sites the the three already showing up here:
    http://1.usa.gov/1NhsVtA

    Press release announcing addition of two clinical sites:
    http://bit.ly/1NhsVtC

    Most patients in this trial would normally progress to severe OM. Even though the trial is blinded, the company should be able to see enough data to know how many actually progress to severe OM. This should give a feel for how the drug is working.
    Aug 18, 2015. 12:55 PM | 4 Likes Like |Link to Comment
  • Cellceutix: Empty Office, Unviable 'Science', Misleading Disclosures, 96% Downside [View article]
    BuyersStrikeWP...Dr Menon didn’t create the bio stating his degree was from Harvard. The original mistake was copied all over the internet. Whomever created the bio on the nnvc site copied it just like everyone else did. Amazingly, even ctix copied it incorrectly when they copied and pasted from the nnvc site for expediency. It was corrected once pointed out.
    Aug 14, 2015. 02:59 PM | 4 Likes Like |Link to Comment
  • Cellceutix: Small Biotech With High Risk / High Reward Profile [View article]
    $CTIX - My visit to Cellceutix, the biotech that a short seller recently called a sham

    http://bit.ly/1IR4I70

    Quote
    "The two took me on a tour of the 12,000 square foot facility, including the labs, where I saw three people who appeared to be researchers. The company as a whole has just 14 employees, some of whom do not work onsite, as they are involved in the company’s clinical trials at Dana-Farber and Brigham and Women’s Hospital. According to the federal website that tracks clinical trials, the company has conducted a total of five trials, three of which are ongoing."
    Aug 14, 2015. 02:22 PM | 3 Likes Like |Link to Comment
  • Cellceutix: Small Biotech With High Risk / High Reward Profile [View article]
    CTIX posted the following letter to SA on the their website for shareholders to see. I don't know whether it was pr'd or not since I haven't seen it come out as a pr.

    http://bit.ly/1J1Ye4A
    Aug 13, 2015. 09:46 AM | 2 Likes Like |Link to Comment
  • Cellceutix: Small Biotech With High Risk / High Reward Profile [View article]
    Dr. Ten Bagger...

    I understand your concern since biotech otc’s are definitely risky. However, the Brilacidin phase IIb has derisked this investment for me. The phase III should start by the end of the year and antibiotic trials run relatively quickly. This trial has a high probability of success based on the phase IIb results.

    Plus, how many scams have you found that have a phase III about to start?

    In reviewing the filings I see an incorrect phone number that wasn’t corrected after the move to the old Kard facilities in the same building. A bit sloppy, but, not criminal.

    Dr Menon didn’t create the bio stating his degree was from Harvard. The original mistake was copied all over the internet. Whomever created the bio on the nnvc site copied it just like everyone else did. Amazingly, even ctix copied it incorrectly when they copied and pasted from the nnvc site for expediency. It was corrected once pointed out.

    The following amended agreement shows that Dr Menon assigned all rights to the Kevetrin patent to CTIX. Dr Menon can’t take the patent if for some reason he left Cellceutix.
    Here’s the filed agreement:
    http://1.usa.gov/1Tw5cVh

    Regarding press releases, I think they should hire a professional IR company.

    Regarding the application to uplist, I believe they shouldn’t say another word about it until the pending application is actually approved. However, hindsight is always easy. I can understand how the last thing the CEO expected was to see the price dropping with all of the upcoming catalysts.

    Yet, with the above mentioned flaws, the company has been excellent in moving the trials forward. Especially, the Brilacidin phase IIb. It’s wasn’t long after they picked up the PolyMedix assets before Dr Menon figured out how to optimize the dosing to avoid the issues the Polymedix phase IIa ran into. The excellent results in the ABSSSI phase IIb trial show it was the correct move. The picking up of those assets and figuring out how to mine them for the gold was quite brilliant.

    The Kevetrin phase I trial has been very slow, but, that’s not the companies fault. Dana Farber is running the trial and the patients are stage 4 cancer patients. They must be treated with care. Oncology trials just run slow. Sadly… for the patients that might like to try the drug asap.

    Good luck in all of your trades. ;)
    Aug 13, 2015. 02:39 AM | 6 Likes Like |Link to Comment
  • Cellceutix: Small Biotech With High Risk / High Reward Profile [View article]
    Slava22... They aren't a shell company.

    Just follow the trials and see how it all comes out. One of these days you'll likely see a New Drug Application *NDA* filed.
    Aug 12, 2015. 09:55 PM | Likes Like |Link to Comment
  • Cellceutix: Small Biotech With High Risk / High Reward Profile [View article]
    Slava22... Some of your general points about early stage biotechs have some truth. However, CTIX isn't a shell to milk retail. Are you aware that when Leo took over from the previous CEO the company was on the brink of bankruptcy? Leo and Dr Menon supported the company with their own funds and deferred salaries for a few years. Scamsters don't do that.

    Leo isn't the perfect manager and has put out some pr's that I would have sat on. However, Leo has also moved the pipeline along very quickly with minimal dilution due to being frugal with company funds.

    In 2012 there was only one trial listed on this site. Look at it now:
    http://1.usa.gov/1CCGluY

    The misinformation and twisting of fact for ones short position is what is immoral. Twisting either way, for long or short is wrong.

    Time will tell about the science as the trials complete.

    In the meantime, go to the company website and take a look at the presentations. http://bit.ly/1UDhtJQ

    Btw, I don't know if it was luck or brilliance, but, the move to pick up the PolyMedix assets out of bankruptcy appears to have been a great move. And, Dr Menon's move to change up the dosing for the Brilacidin phase IIb ABSSSI trial turned out to be the correct move based on the trial results. (Look at presentation in Copenhagen and again in NY)

    Good luck in your trading and let's simply agree to disagree. ;)

    Disclosure.... I hold long.
    Aug 12, 2015. 03:12 PM | 6 Likes Like |Link to Comment
  • Cellceutix: Small Biotech With High Risk / High Reward Profile [View article]
    Good article Dr Snuderl... ;)

    It's good to have someone with your credentials highlight inaccuracies in the shorting article that was designed to manipulate the share price down.

    I have nothing against shorting. It's simply a trading tool, but, to present inaccuracies to facilitate their trading position was wrong.
    Aug 12, 2015. 11:47 AM | 8 Likes Like |Link to Comment
  • Cellceutix: Empty Office, Unviable 'Science', Misleading Disclosures, 96% Downside [View article]
    Read the following press release to learn more about the science being inaccurately stated as fact in this article.

    http://bit.ly/1KXy5HR
    Aug 9, 2015. 02:22 PM | 3 Likes Like |Link to Comment
  • Cellceutix: Empty Office, Unviable 'Science', Misleading Disclosures, 96% Downside [View article]
    I actually made a typo in my first comment. Meant to say "The article states that only 60% of ovarian cancers have defective p53 genes." Whereas it's actually 96% per the nih link I gave above. ;)
    Aug 9, 2015. 01:52 PM | 4 Likes Like |Link to Comment
  • Cellceutix: Empty Office, Unviable 'Science', Misleading Disclosures, 96% Downside [View article]
    I found the relevant study to back up my over 90% statement in my above comment:

    http://1.usa.gov/1Ta7RZX

    "The Cancer Genome Atlas Project has performed whole exome sequencing on ovarian cancer.92 Analyzing DNA from 316 high-grade serous ovarian cancer samples and matched normal samples for each individual, 19,356 somatic mutations (about 61 per tumor) were annotated. High-grade serous ovarian cancer is characterized by TP53 mutations in almost all tissues (96%)."

    The scientific facts in this article are incorrect.
    Aug 9, 2015. 01:16 PM | 4 Likes Like |Link to Comment
  • Cellceutix: Empty Office, Unviable 'Science', Misleading Disclosures, 96% Downside [View article]
    The "biochemist" that supposedly reviewed the Kevetrin information is at best misinformed and at worst intentionally targeting Cellceutix to bring down its stock price. The article states that only 50% of ovarian cancers have defective p53 genes. This is a significant fraction if one considers that most approved drugs are effective for anywhere from 10-30% of patients. Also, the Cancer Genome Atlas reported that out of 316 high grade serous patients, over 90% had p53 defects. So this point is both wrong on the facts and on merit.

    Also, the Brilacidin ABSSSI trial wasn't attacking a gram negative organisim. The company is working on gram negative in preclinicals, but, haven't tested that formulation of Brilacidin in a clinical setting yet.

    The scientific facts in this article are incorrect.
    Aug 9, 2015. 12:33 PM | 7 Likes Like |Link to Comment
  • Interview With Dr Christopher Missling, CEO Of Anavex [View article]
    That's a good find.

    " Dr V. did refuse to sign, it seems - and for obvious reasons - but his signature isn't required per 35 U.S.C. § 262. "

    It will be fascinating to watch this one play out. I picked some shares up after the pr a few days ago. ;)
    Jul 24, 2015. 01:33 PM | Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    $CTIX - Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
    http://bit.ly/1ebMfcp
    Jul 20, 2015. 11:43 AM | 2 Likes Like |Link to Comment
  • Cellceutix's Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer [View article]
    Orphan drug status for Kevetrin is excellent news. Especially, since the phase I safety trial isn't ended yet! ;)

    http://1.usa.gov/1V4mmwJ

    All of their trials can be found here: http://1.usa.gov/1CCGluY
    Jul 15, 2015. 04:08 PM | Likes Like |Link to Comment
COMMENTS STATS
438 Comments
773 Likes